# Michaela Mattheus

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/michaela-mattheus/

## Facts

| Field | Value |
| --- | --- |
| Citations | 20,334 |
| Field | Diabetes Treatment and Management |
| h-index | 33 |
| i10-index | 56 |
| Last Known Institution | Boehringer Ingelheim (Germany) |
| OpenAlex ID | https://openalex.org/A5081837566 |
| ORCID iD | https://orcid.org/0000-0002-8611-6236 |
| Works | 142 |

## Researcher papers

- [Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes](https://scholariq.org/papers/empagliflozin-cardiovascular-outcomes-and-mortality-in-type-2-diabetes/)
- [Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes](https://scholariq.org/papers/empagliflozin-and-progression-of-kidney-disease-in-type-2-diabetes/)
- [Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes](https://scholariq.org/papers/effect-of-linagliptin-vs-glimepiride-on-major-adverse-cardiovascular-outcomes-in/)
- [Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease](https://scholariq.org/papers/empagliflozin-and-clinical-outcomes-in-patients-with-type-2-diabetes-mellitus/)
- [Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial](https://scholariq.org/papers/effects-of-empagliflozin-on-the-urinary-albumin-to-creatinine-ratio-in-patients/)
- [Empagliflozin after Acute Myocardial Infarction](https://scholariq.org/papers/empagliflozin-after-acute-myocardial-infarction/)
- [Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial](https://scholariq.org/papers/empagliflozin-and-kidney-function-decline-in-patients-with-type-2-diabetes-a/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Hyperglycemia and glycemic control in critically ill and hospitalized patients](https://scholariq.org/topics/hyperglycemia-and-glycemic-control-in-critically-ill-and-hospitalized-patients/)

## Researcher university

- [Boehringer Ingelheim (Germany)](https://scholariq.org/institutions/boehringer-ingelheim-germany/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.